Hormonal
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.
GLP-1 RAs like semaglutide and tirzepatide are highly effective medications for weight loss, producing 15-22% body weight loss in clinical trials. They work by mimicking gut hormones to reduce appetite and improve metabolic health. They are not a 'magic bullet' but a tool that works best when combined with dietary changes, physical activity, and psychological support. Common side effects like nausea are usually temporary and manageable. These drugs are particularly useful for those who have struggled with long-term weight maintenance through lifestyle changes alone.
The STEP-1 RCT demonstrated the efficacy and safety of Semaglutide 2.4 mg... with a mean weight loss of 15%... The subsequent SURMOUNT RCT demonstrated that the dual GLP-1/GIP... RA, Tirzepatide, showed greater efficacy with participants losing 22.5% at 72 weeks... the SELECT trial... showed participants using Semaglutide 2.4 mg had a 20% reduction in major adverse cardiovascular events
Why this rating
Based on multiple large-scale RCTs (STEP-1, SURMOUNT, SELECT) cited in the text.
Source
“From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of <scp>GLP</scp>‐1 receptor agonists in obesity management services
Adrian Brown et al. · Nutrition Bulletin · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →